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http://dx.doi.org/10.1016/j.jmii.2015
1684-1182/Copyright ª 2015, TaiwanAbstract Objective: The main objective of this study was to evaluate the efficacy and safety
of Lactobacillus rhamnosus in children aged 4e48 months with atopic dermatitis.
Methods: The design of this study was a two-center, double-blind, randomized, and placebo-
controlled study with two parallel groups to evaluate the efficacy and safety profile of L. rham-
nosus in children aged 4e48 months with atopic dermatitis diagnosed using Hanifin and Rajka
criteria and with a Scoring of Atopic Dermatitis (SCORAD)  15 at enrollment. The duration of
this study was 8 weeks with a total of five visits. The enrolled patients were allocated into
either a treatment group (one ComProbi capsule containing L. rhamnosus a day) or a control
group (one capsule of placebo a day) at a ratio of 1:1. The primary endpoint was to compare
the mean change from baseline in SCORAD after 8 weeks of treatment. The other secondary
end points were to compare the following: the mean changes from baseline in SCORAD at post-
baseline visits, the frequency and total amount of the use of corticosteroids during the 8-week
treatment, the frequency of atopic dermatitis and the symptom-free duration, the meanAllergy, Immunology, and Rheumatology, Department of Pediatrics, Chung Shan Medical University
guo North Road, Taichung City 40201, Taiwan, ROC.
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nology and Infection (2015), http://changes from baseline in Infant Dermatitis Quality of Life Questionnaire at Week 4 and Week 8,
and the mean changes from baseline in the Dermatitis Family Impact Questionnaire at Week 4
and Week 8.
Results: The mean changes in SCORAD from baseline at Week 8 was 21.69  16.56 in the L.
rhamnosus group and 12.35  12.82 in the placebo group for the intent-to-treat population
(p Z 0.014). For the per-protocol population, the mean change of SCORAD from baseline was
23.20  15.24 in the L. rhamnosus group and 12.35  12.82 in the placebo group
(pZ 0.003). Significant differences were demonstrated between groups at Week 8 in intensity
in the intent-to-treat population and per-protocol population. Throughout the period, the
amount of topical corticosteroids used showed no difference between groups. No significant
difference was noted in the overall symptom-free durations compared with the placebo group.
Infant Dermatitis Quality of Life Questionnaires and Dermatitis Family Impact Questionnaires
scores improved significantly at Week 4 and Week 8 but did not reach statistical significance.
Adverse events were documented in 14/33 patients in the L. rhamnosus group (42.42%, 35
events) and in 15/33 placebo patients (45.45%, 37 events).
Conclusions: The results of this study indicated that L. rhamnosus was effective in decreasing
symptoms of atopic dermatitis after an 8-week treatment by comparing the mean change of
SCORAD from baseline with a placebo (p < 0.05). The reduction in SCORAD resulted from a
consistent decrease in all components of SCORAD. Patients who took L. rhamnosus for 8 weeks
expressed less SCORAD in the three components: area of affected skin, intensity of atopic
dermatitis, and patient symptoms, with a significant decrease in the mean change of intensity
from baseline compared with placebo.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Atopic dermatitis (AD) is a chronic inflammatory skin dis-
ease with various degrees of remission and relapsing cour-
ses which, in nearly half of cases, has an allergic origin. Skin
barrier due to a genetic defect plays an important role in
AD. Mutations of the filaggrin gene, located in the
epidermal differentiation complex, have been identified as
a strong predisposing factor for AD.1 The skin inflammation
can be caused by a variety of triggers, including allergens,
food allergens, dust mites, weather changes, temperature
changes, and stress. It affects about 5e20% of children
worldwide and the incidence is increasing year by year;2e4
and the same trend was also noted from 1.3% in 1974 up to
12.9% in 2007 in Taiwan.5 AD is becoming a major problem
in industrialized countries.2,3
The treatment strategies of childhood AD include
traditional topical corticosteroids, a topical calcineurin
inhibitor, phototherapy, and immunosuppressants.6e8 All
these treatment methods are useful and the onset is fast.
However, the side effects must be monitored for longterm
use. Side effects such as skin atrophy, changes in pigmen-
tation, and easy bruising were noted, especially in vulner-
able infants and children.
Allergic diseases are associated with a shift in T helper
(Th1/Th2) cytokine balance toward a Th2 response. Pro-
biotics can inhibit the Th2 response, especially early in life,
while stimulating the production of Th1 cytokines, such as
interferon gamma.9e12 In addition, decreases in regulatory
T cells, which are crucial regulators of the immune
response, have been reported in patients with AD, and their
numbers are inversely correlated with immunoglobulin EWu Y-J, et al., Evaluation of e
: An 8-week, double-blind, rando
dx.doi.org/10.1016/j.jmii.2015.10(IgE), eosinophilia, and interferon gamma levels.13,14 Pro-
biotics upregulated the generation of regulatory T cells,
which migrated to inflammation sites and suppressed dis-
ease progression in mice.15 When ingested, probiotics may
have a positive effect in the treatment or prevention of
specific diseases,16 and have been shown to modulate the
mucosal immune response and reduce gastrointestinal
inflammation in infants with food allergies.17 Suggested
mechanisms of probiotics include: (1) stimulation of
epithelial mucin production;18 (2) enhanced production of
secretory IgA;19e21 and (3) alleviation of intestinal inflam-
mation by stimulation of anti-inflammatory cytokines.22,23
Atopic children have been reported to harbor more Clos-
tridia and fewer Bifidobacteria and Lactobacilli in their gut
flora than nonatopic children.24 Probiotics can potentially
modulate the toll-like receptors and the proteoglycan
recognition proteins of enterocytes, leading to activation of
dendritic cells and a Th1 response.24 Therefore, as an
alternative treatment, probiotics7,25 are suggested to pre-
vent and treat allergic diseases, such as AD and allergic
rhinitis, and even in that context their clinical use is
controversial. The main objective of this study is to eval-
uate the effect of probiotics, Lactobacillus rhamnosus, in
treating children aged 4e48 months suffering from AD.Materials and methods
Patient and study design
The design of this study was a two-center, double-blind,
randomized, and placebo-controlled study with twofficacy and safety of Lactobacillus rhamnosus in children aged
mized, placebo-controlled study, Journal of Microbiology, Immu-
.003
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L. rhamnosus in children aged 4e48 months with AD diag-
nosed using Hanifin and Rajka criteria and with a Scoring of
Atopic Dermatitis (SCORAD)  15 at enrollment. The study
was conducted at two sites, Chung Shan Medical University
Hospital and Taipei City Hospital, Ren-Ai branch. The
duration of this study was 8 weeks with a total of five visits.
The enrolled patients were allocated into either a treat-
ment group [one capsule of ComProbi containing 350 mg L.
rhamnosus (MP108) and maltodextrin a day; CY Biotech,
Taipei, Taiwan] or a control group (one capsule of malto-
dextrin only a day) at a ratio of 1:1. For patients who could
not swallow capsules, parents were instructed to mix the
powder in water, milk, breast milk, or food heated to
<40C. The patients with clinically evident infection in skin
lesions, severe asthma or acute asthma attack within
3 months, autoimmune disease, immunodeficiency, expo-
sure to phototherapy, or having used systemic corticoste-
roids within 1 month, antihistamine within 7 days, or
topical calcineurin inhibitor within 1 month were all
excluded. Rescue medication, Cutivate cream (Glax-
oSmithKline, Durham, U.K.), the topical corticosteroid, was
provided to each patient in case of uncontrolled symptoms.
It was used on an as-needed basis, as and when symptoms
arise (on demand). When it was used, the patients’ legally
acceptable representatives were asked to record the fre-
quency of use in diary cards. The amount of remaining
rescue medication was monitored at each visit.
Clinical evaluation
Evaluation of each component of SCORAD was standardized
by giving examples of the area counting method, rule of
nine, and examples of the intensity in each symptom.
Evaluation of subjective symptoms was standardized by a
visual analog scale with a line of 10 cm, which is typically
used.
The primary efficacy end point of this study was to
compare the mean change of SCORAD after the 8-week
treatment. The secondary efficacy end points were the
following: (1) to compare the mean changes of SCORAD at
postbaseline visits; (2) to compare the frequency and total
amounts of the use of corticosteroids during the 8-week
treatment; (3) to compare the frequency of AD and the
symptom-free duration; (4) to compare the mean changes
from baseline in Infant Dermatitis Quality of Life Ques-
tionnaire (IDQOL) at Week 4 and Week 8; and (4) to
compare the mean changes from baseline in Dermatitis
Family Impact Questionnaire (DFI) at Week 4 and Week 8.
Intent-to-treat (ITT) population means patients who take at
least one dose of study medication and have at least one
efficacy measurement. Per-protocol (PP) population means
a patient of ITT with a drug compliance rate over 80%. The
compliance was evaluated based on numbers of the
returned medication.
Statistical methods
The study was designed to investigate the superiority of L.
rhamnosus compared with a placebo control based on the
mean change of SCORAD score from baseline after an 8-Please cite this article in press as: Wu Y-J, et al., Evaluation of e
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nology and Infection (2015), http://dx.doi.org/10.1016/j.jmii.2015.10week treatment. The primary endpoint was analyzed with
the ManneWhitney test based on a one-tailed test with a
significance level of 0.025. If the related p value is less than
0.025, the superiority will be demonstrated. Two-sided
tests of significance were used with a significance level of
0.05 for secondary endpoint analysis. The continuous sec-
ondary efficacy variables were performed by means of a t
test. The difference between the two treatments was given
along with its 95% confidence interval. Statistical analysis
for categorical secondary efficacy variables was performed
by means of Chi-square test or Fisher’s exact test.
Results
Characteristics of the study population
This randomized, double-blind, placebo-controlled study
was conducted at two sites in Taiwan to investigate the
efficacy and safety of L. rhamnosus (MP108) in children
(aged 4e48 months) with AD. At baseline visit (Visit 1), a
total of 67 patients were screened for eligibility and
assigned to either the L. rhamnosus (MP108) group or pla-
cebo group randomly at a ratio of 1:1 for 8 weeks.
During the study period, five patients discontinued the
study, one was excluded due to investigator’s concern, and
the others were withdrawn because of taking prohibited
medications. Therefore, 66 patients who had taken at least
one dose of the study drugs were included in the safety
population. Among the 66 patients who had at least one
evaluable data point for efficacy assessment were included
in the ITT population. The 62 patients who fulfilled the ITT
definition, had a primary efficacy measurement, without
any protocol violations, and with a drug compliance rate 
80%, were categorized as the PP population. A detailed
disposition is presented in Figure 1.
No significant difference was observed in the de-
mographic and baseline characteristics such as age, height,
and weight (Table 1). The treatment compliance between
the two groups was also not found to be statistically
significant.
Though the SCORAD for the placebo group showed more
severity than for the L. rhamnosus group, no significant
differences were noted in SCORAD between the groups.
The SCORAD and each component of SCORAD obtained at
baseline and posttreatment visits are demonstrated in
Figures 2 and 3. A significant reduction in both SCORAD and
each component of SCORAD was observed in both groups
from Week 2. However, no significant differences were
observed between the groups.
The analysis for primary efficacy endpoint
The primary efficacy was assessed through the SCORAD
index which concerned lesion spread, intensity, and sub-
jective symptoms.
Table 2 presents the results of the mean change from
baseline in SCORAD after an 8-week treatment for both
populations. At the end of Week 8, the severity of AD
tended to reduce in both groups significantly. The mean
change in SCORAD from baseline on the 8th week was
21.69  16.56 in the L. rhamnosus (MP108) group andfficacy and safety of Lactobacillus rhamnosus in children aged
mized, placebo-controlled study, Journal of Microbiology, Immu-
.003
Figure 1. Trial profile showing patient population analyzed for efficacy of the probiotics.
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patients (p Z 0.005). For the PP population, the mean
change of SCORAD from baseline was 23.20  15.24 in the
L. rhamnosus group and 12.35  12.82 in the placebo
group (p Z 0.002).
Analysis for mean changes of SCORAD components from
baseline at Week 8 is provided in Table 3. Significant im-
provements were observed as reductions in the skin surface
with AD, intensity of AD, and subjective symptoms in both
groups. The mean changes from baseline at Week 8 in
surface area, intensity, and subjective symptoms wereTable 1 Summary of demographics of the intent-to-treat popu
ITT populatio
LR, n Z 33 Pla
Age
(y)
Mean  SD 1.5  1.1 1.8
Median 1.0 1.8
Range (0.3, 3.5) (0.3
95% CI (0.3, 3.5) (1.4
pa (95% CI) 0.241 (0.9, 0.2)
Sex Male, n (%) 25 (75.8) 19
Female, n (%) 8 (24.2) 14
pb (95% CI) 0.158
Weight
(kg)
Mean  SD 10.6  3.0 11.
Median 10.0 10.
Range (6.2, 17.0) (7.5
95% CI (9.6, 11.7) (10
pa (95% CI) 0.258 (2.5, 0.7)
Height
(cm)
Mean  SD 78.2  12.9 82.
Median 75.0 81.
Range (60.0, 103.0) (63
95% CI (73.6, 82.8) (78
pa (95% CI) 0.122 (10.8, 1.3)
a t test.
b Chi-square test.
CI Z confidence interval; ITT Z intent to treat; LR Z Lactobacillus
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nology and Infection (2015), http://dx.doi.org/10.1016/j.jmii.2015.1013.66  14.42 versus 7.21  8.99 (L. rhamnosus vs.
placebo, p Z 0.2510), e3.91  3 .57 versus 2.06  2.77
(L. rhamnosus vs. placebo, p Z 0.0121), and 5.47  5.32
versus 3.69  4.25 (L. rhamnosus vs. placebo, pZ 0.0858)
in the ITT population. For the PP population, the mean
changes were 14.40  14.49 versus 7.21  8.99 in sur-
face area (L. rhamnosus vs. placebo, p Z 0.1786),
e4.13  3.55 versus 2.06  2.77 in intensity (L. rham-
nosus vs. placebo, p Z 0.0053) and 5.93  4.52 versus
3.69  4.25 (L. rhamnosus vs. placebo, p Z 0.0545) in
subjective symptoms score.lation and per-protocol population.
n PP population
cebo, n Z 33 LR, n Z 30 Placebo, n Z 32
 1.1 1.4  1.1 1.8  1.1
0.9 1.8
, 3.9) (0.3, 3.5) (0.3, 3.9)
, 2.2) (1.0, 1.8) (1.4, 2.3)
0.144 (1.0, 0.1)
(57.6) 24 (80.0) 18 (56.3)
(42.4) 6 (20.0) 14 (43.7)
0.064
5  3.4 10.5  3.0 11.6  3.4
0 9.9 10.3
, 21.0) (6.2, 17.0) (7.5, 21.0)
.4, 12.7) (9.3, 11.6) (10.4, 12.8)
0.180 (2.8, 0.5)
9  11.7 77.1  12.7 83.0  11.8
5 72.0 81.8
.0, 112.0) (60.0, 103.0) (63.0, 112.0)
.8, 87.1) (72.4, 81.8) (78.8, 87.3)
0.062 (12.2, 0.3)
rhamnosus; PP Z per-protocol; SD Z standard deviation.
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Figure 2. The comparison of Scoring of Atopic Dermatitis between the treatment groups during treatment in the intent-to-treat
population and per-protocol population. * Statistically significant. Statistical method: paired t test (within group). ITTZ intent-to-
treat; LR Z Lactobacillus rhamnosus; Pbo Z placebo; PP Z per-protocol; SCORADZ Scoring of Atopic Dermatitis.
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mean change of SCORAD after the 8-week treatment be-
tween the groups in ITT and PP populations. Furthermore,
statistically significant differences were found in mean
changes in intensity between the groups in ITT and PP
populations.
The analysis for secondary efficacy endpoints
Secondary efficacy endpoints included comparing the
following: the mean changes from baseline in SCORAD,
frequency and total amount of use of topical corticoste-
roids during the 8-week treatment, frequency of AD and the
symptom-free duration, mean changes from baseline in
IDQOL at Week 4 and Week 8, and mean changes from
baseline in DFI at Week 4 and Week 8.
As shown in Table 4, the mean changes in SCORAD at
Week 2, Week 4, and Week 6 were also analyzed. For the
ITT population, patients receiving L. rhamnosus (MP108)
were found to experience greater reduction in SCORAD
scores, with the values of 13.34  13.10, e16.65  10.68,
and 20.50  13.94 versus 10.12  9.00, 11.97  9.62,
and 13.42  10.37 in the placebo group at Visit 2 (Week
2), Visit 3 (Week 4), and Visit 4 (Week 6), respectively. With
regard to the PP population, the mean changes in SCORAD
compared with baseline at Visit 2, Visit 3, and Visit 4 in the
L. rhamnosus (MP108) group were 14.51  13.11,
17.44  10.60, and 21.36  13.79 versus 10.29  9.09,
11.97  9.62, and 13.42  10.37 in the placebo group,
respectively. Mean change in SCORAD reach obviously
decreased in the L. rhamnosus group compared to the
placebo group from Visit 6 in the ITT population and Visit 4
in the PP population.
During the study, the total amount of topical cortico-
steroids used in the L. rhamnosus (MP108) group and the
placebo group were 5.87  7.48 g versus 4.73  5.48 g for
the ITT population, and 6.01  7.77 g versus 4.49  5.52 g
for the PP population, with no significant differences be-
tween the groups for the two populations. The frequency of
topical corticosteroid use showed no significant differences
(data not shown).
The overall symptom-free durations for AD are
0.58  0.27 versus 0.65  0.25 (L. rhamnosus vs. placebo)Please cite this article in press as: Wu Y-J, et al., Evaluation of e
4e48 months with atopic dermatitis: An 8-week, double-blind, rando
nology and Infection (2015), http://dx.doi.org/10.1016/j.jmii.2015.10for the ITT population, and 0.59  0.26 versus 0.65  0.26
for the PP population. After treatment with L. rhamnosus,
no significant difference was noted at each post-treatment
visit compared with the placebo (data not shown).
Compared with the baseline, the mean changes in DFI
(Table 5) at Week 4 and Week 8 for the ITT population and
PP population showed a decline. DFI reduced significantly
at Week 4 and Week 8 along with the treatment period in
both groups. However, no statistically significant differ-
ences were observed between the groups. As for IDQOL
(Table 6), we also recorded at Week 4 and Week 8. Mean
changes from baseline declined in the ITT population and
PP population, but no statistically significant differences
were noted.
Assessment of safety
The vital signs, including blood pressures, pulse rate (or
heart rate), respiratory rate, and ear temperature, were
summarized by descriptive statistics as well as the mean
change from baseline. No significant difference was noted
for values of vital sign, pulse rate, respiratory rate, and
body temperature at each posttreatment visit between the
groups. Also, most of the changes in physical examinations
did not reach significant difference. Besides, adverse
events were monitored and data showed no relation to our
study products (data not shown).
Discussion
The role of probiotics in the treatment of AD remains
controversial. There are several studies published. Some
studies25e29 suggested that there was a statistically signif-
icant decrease in SCORAD after probiotics ingested by in-
fants or children with AD for 1 month or 2 months compared
with that after placebo, while some studies26,30,31 showed
that SCORAD was significantly reduced after treatment with
Lactobacilli only in children with IgE-associated AD, i.e.,
treatment with Lactobacilli may alleviate AD symptoms in
IgE-sensitized infants but not in non-IgE-sensitized infants.
In the study by Rosenfeldt et al,26 the effect of probiotics in
AD treatment was more pronounced in patients with afficacy and safety of Lactobacillus rhamnosus in children aged
mized, placebo-controlled study, Journal of Microbiology, Immu-
.003
Figure 3. The comparison of Scoring of Atopic Dermatitis items between the treatment groups during treatment in the intent-to-
treat population and per-protocol population. * Statistically significant. Statistical method: paired t test (within group).
ITT Z intent-to-treat; LR Z Lactobacillus rhamnosus; Pbo Z placebo; PP Z per-protocol.
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However, in some studies,32e34 the change in SCORAD was
not statistically significant between probiotic- and placebo-
treated children. Therefore, the effect of probiotics on AD
treatment was controversial.
There is some evidence that intestinal inflammation
and disruption of the intestinal barrier function is involved
in the pathogenesis of AD.35 Probiotics have been shown in
a number of studies to alleviate intestinal inflammation.
Lactobacillus species showed the most potent inhibitory
activity against the growth of Staphylococcus aureus,
which was found to be one of the causes of exacerbation ofPlease cite this article in press as: Wu Y-J, et al., Evaluation of e
4e48 months with atopic dermatitis: An 8-week, double-blind, rando
nology and Infection (2015), http://dx.doi.org/10.1016/j.jmii.2015.10AD.36 Therefore, probiotics may have a beneficial role in
AD treatment due to the inhibitory effect on S. aureus. In
the study by Iemoli et al,35 probiotics were shown to be
well tolerated, and resulted in the colonization of gut
microbiota and beneficial clinical effects in AD, which
suggests that probiotic supplements could be a beneficial
adjunct therapy for treating AD. In another study,37 pro-
biotic bacteria enhanced murine and human intestinal
epithelial barrier functions. Other mechanisms that may
be due to the effect of Lactobacillus species in reducing
allergen-induced skin inflammation is by regulating inter-
leukin (IL)-4 and IgE. In an animal study,38 probiotic strainsfficacy and safety of Lactobacillus rhamnosus in children aged
mized, placebo-controlled study, Journal of Microbiology, Immu-
.003
Table 2 Mean change from baseline in Scoring of Atopic Dermatitis after an 8-week treatment.
Mean change in SCORADa ITT population PP population
LR (MP108) Placebo LR (MP108) Placebo
Mean  SD 21.69  16.56 12.35  12.82 23.20  15.24 12.35  12.82







a SCORADZ Area/5 þ 7  intensity/2 þ subjective symptoms.
b ManneWhitney (between groups).
* Statistically significant.
CI Z confidence interval; ITT Z intent to treat; LR Z Lactobacillus rhamnosus; PP Z per-protocol; SCORADZ Scoring of Atopic
Dermatitis; SD Z standard deviation.
Table 3 Mean change from baseline in the components of Scoring of Atopic Dermatitis after an 8-week treatment.
Components of SCORAD ITT population PP population
LR (MP108) Placebo LR (MP108) Placebo
Area Mean  SD 13.66  14.42 7.21  8.99 14.40  14.49 7.21  8.99
pa 0.2510 0.1786
Intensity Mean  SD 3.91  3.57 2.06  2.77 4.13  3.55 2.06  2.77
pa 0.0121* 0.0053*
Subjective symptom Mean  SD 5.47  5.32 3.69  4.25 5.93  4.52 3.69  4.25
pa 0.0858 0.0545
a ManneWhitney test (between groups).
* Statistically significant.
CI Z confidence interval; ITT Z intent to treat; LR Z Lactobacillus rhamnosus; PP Z per-protocol; SCORADZ Scoring of Atopic
Dermatitis; SD Z standard deviation.
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+ MODELisolated from kimchi suppress house dust mite-induced
dermatitis in an NC/Nga mouse, which suggests that Lac-
tobacilli inhibiting AD probably resulted from altering the
balance of the Th1/Th2 ratio. In the study by Kalliomaks
et al,39 probiotics were proven to be effective in the
prevention of early atopic disease in children with high
risk.Table 4 Mean change in Scoring of Atopic Dermatitis at










Wk 2 Mean change 13.34 10.12 14.51 10.29
pa 0.25 0.15
Wk 4 Mean change 16.65 11.97 17.44 11.97
pa 0.07 0.04*
Wk 6 Mean change 20.50 13.42 21.36 13.42
pa 0.03* 0.01*
a ManneWhitney test (between groups).
* Statistically significant.
ITTZ intent to treat; LRZ Lactobacillus rhamnosus; PPZ per-
protocol; SCORADZ Scoring of Atopic Dermatitis.
Please cite this article in press as: Wu Y-J, et al., Evaluation of e
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nology and Infection (2015), http://dx.doi.org/10.1016/j.jmii.2015.10Our study suggests a positive effect of probiotic sup-
plementation in patients with AD. There is a clinical
observation also favoring this theory with the demonstra-
tion that probiotic supplements could alleviate atopic
eczema in children.40
Our data showed a greater decrease in the mean SCORAD
score for the ITT population than for children from the
placebo group at Week 8 (21.69 vs. e12.35, respectively;
pZ 0.014). The same result was noted in the PP population
(23.20 vs. 12.35, respectively; pZ 0.002; Table 2). Each
of the SCORAD items (intensity score, subjective itch score,
and extent) were analyzed separately (Table 3).
Besides each component of the SCORAD, the area and
intensity decreased after 8 weeks of treatment and
reached the level of significance (p < 0.05) in the ITT and
PP populations. We also saw a mean change of SCORAD
that decreased from Week 4 and reached the level of
significance and the outcome persisted to Week 8 (Table
4). IDQOL and DFI scores decreased from baseline in the
probiotic group and placebo group, but our data are not
statistically significant. Use of topical corticosteroids
during the 8-week trial period in the L. rhamnosus (MP108)
group and the placebo group showed no significant
difference.
Although a significantly greater reduction of SCORAD was
seen in the L. rhamnosus group than in placebo group, the
SOCRAD were similar between the groups at Week 8. That
might explain why there is no difference in IDQOL and DFIfficacy and safety of Lactobacillus rhamnosus in children aged
mized, placebo-controlled study, Journal of Microbiology, Immu-
.003
Table 5 Mean change of Dermatitis Family Impact Questionnaire at Week 4 and Week 8 in the intent-to-treat population and
per-protocol population.
Mean change of DFI ITT population PP population
LR(MP108) Placebo LR(MP108) Placebo
Wk 4 Mean change 4.2 4.3 4.3 4.3
pa 0.57 0.54
Wk 8 Mean change 6.0 5.4 6.2 5.4
pa 0.61 0.46
a Wilcoxon signed rank test (between groups).
DFI Z dermatitis family impact questionnaires; ITT Z intent to treat; LR Z Lactobacillus rhamnosus; PP Z per-protocol.
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+ MODELscores. However, the onset of probiotics may be much more
significant when treated for more than 8 weeks, which is
one of our limitationsdlack of longterm follow up. Due to
the fluctuating nature of AD, the disease activity can fluc-
tuate widely in the short term. Another limitation is lack of
other laboratory data evaluation, total IgE, or IL-4, which
can evaluate the allergic constitution. Serum levels of cy-
tokines can provide a more objective evaluation. A possible
limitation of our study is that patients were allowed to use
topical corticosteroids. Because corticosteroids are the
mainstay treatment of AD, it would be unethical to with-
hold this treatment. Therefore, the combined treatment
may be practical and the synergistic effect was observed in
our study. However, corticosteroid use was carefully
monitored and collected during the treatment period. In
our study, not only SCORAD, but also DFI and IDQOL were
evaluated for efficacy. Actually, life quality can also be one
way to present the severity of AD and can be used for ef-
ficacy evaluation. Vital signs and any adverse effects were
documented at each visit for safety evaluation. Those pa-
tients with other severe allergic disease or who were under
medication with immunosuppressants were excluded, and
thus the influence of latent variables on efficacy was
decreased. The probiotic efficacy in AD was demonstrated
by the decreased SCORAD. Both efficacy and safety were
reported. Our study implies that the effect of probiotics
was not attributable to dose or duration of probiotic sup-
plementation, as these parameters were similar in children
who did not finish the course of probiotics, which can be
noted through similar results in ITT and PP populations.Table 6 Mean change of Infant Dermatitis Quality of Life
Questionnaires at Week 4 and Week 8 in the intent-to-treat
population and per-protocol population.
Mean change
of IDQOL






Wk 4 Mean change 2.97 2.47 3 2.47
pa 0.71 0.63
Wk 8 Mean change 3.28 3.38 3.53 3.38
pa 0.71 0.65
a Wilcoxon signed rank test (between groups).
IDQOLZ Infant Dermatitis Quality of Life Questionnaire;
ITTZ intent to treat; LRZ Lactobacillus rhamnosus; PPZ per-
protocol.
Please cite this article in press as: Wu Y-J, et al., Evaluation of e
4e48 months with atopic dermatitis: An 8-week, double-blind, rando
nology and Infection (2015), http://dx.doi.org/10.1016/j.jmii.2015.10In summary, administration of probiotic, L. rhamnosus,
to children aged 4e48 months with AD was associated with
the improvement in severity of AD and the product safety
was demonstrated. Our results are in accordance with the
results from experimental studies, as well as those reported
in previous clinical trials. Further studies may address the
effects of probiotic supplementation in a longterm period.
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